USOR 23107 - STAR Ph3 Study of OP-1250 Monotherapy vs SOC for ER+ HER2 mBreast CDK4/6 (OPERA-01)

A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy

Disease Types: STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Chicago Resurrection, Niles